FDA Approves New Treatment for Hypoactive Sexual Disorder

June 25, 2019

The FDA has approved a new treatment for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Vyleesi (bremelanotide) activates melanocortin receptors through injection under the skin.

“There are women who, for no known reason, have reduced sexual desire that causes marked distress, and who can benefit from safe and effective pharmacologic treatment. Today’s approval provides women with another treatment option for this condition,” said Hylton V. Joffe, M.D., M.M.Sc., director of the Center for Drug Evaluation and Research’s Division of Bone, Reproductive and Urologic Products. “As part of the FDA’s commitment to protect and advance the health of women, we’ll continue to support the development of safe and effective treatments for female sexual dysfunction.”

Common side effects of Vyleesi include:


Read the full press release.